Pharmacy No. 84. Delivery of medicines to your home and office.

Delivery on Sundays and holidays does not work!

Medicines

my basket

Apteka84.kz is an online pharmacy that offers its customers medicines, medicinal and decorative cosmetics, dietary supplements, vitamins, baby food, intimate products for adults, medical equipment and thousands of other medical and cosmetic products at low prices. All data presented on the Apteka84.kz website is for informational purposes only and is not a substitute for professional medical care. Apteka84.kz strongly recommends that you carefully read the instructions for use contained in each package of medicines and other products. If you currently have any symptoms of the disease, you should seek help from a doctor. You should always tell your doctor or pharmacist about all the medicines you take. If you feel you need further help, please consult your local pharmacist or contact our GP online or by telephone.

Instructions for use FURAZIDIN

Criteria for the incidence of adverse reactions:

very frequent (>10%), frequent (1-10%), infrequent (0.1-1%), isolated (0.01-0.1%), rare (<0.01%).

From the blood system:

rare - hematopoietic disorders (agranulocytosis, thrombocytopenia, aplastic anemia).

From the nervous system:

uncommon - dizziness, drowsiness;

single - peripheral neuropathy;
rare - headache, mild intracranial hypertension, neuritis, polyneuritis.

From the organs of vision:

Uncommon: visual impairment.

From the respiratory system:

isolated - acute and chronic pulmonary reactions. An acute pulmonary reaction develops rapidly and is manifested by severe shortness of breath, fever, chest pain, cough with or without sputum, eosinophilia (increased number of eosinophilic granulocytes in the blood). It is possible that, simultaneously with an acute pulmonary reaction, the appearance of skin rashes, itching, urticaria, myalgia (muscle pain), angioedema (swelling of the face, neck, oral tissues and larynx). The basis of an acute pulmonary reaction is a hypersensitivity reaction, which can develop over several hours, less often over minutes. The acute pulmonary reaction is reversible and disappears when the drug is stopped. A chronic pulmonary reaction can develop over a long period of time after cessation of treatment with nitrofurans (including furazidine). Characterized by a gradual increase in dyspnea, rapid breathing, unstable fever, eosinophilia, progressive cough and interstitial pneumonitis and/or pulmonary fibrosis.

From the digestive tract:

infrequent - loss of appetite, flatulence, nausea;

single - vomiting, diarrhea;
rare - pancreatitis.

From the skin and subcutaneous tissue:

isolated - papular rashes, itching;

rare - angioedema, urticaria, dermatitis, erythema multiforme.

From the musculoskeletal system:

rare - arthralgia (joint pain).

General violations:

isolated - weakness, increased body temperature.

From the hepatobiliary system:

rare - cholestatic jaundice, hepatitis, liver dysfunction.

Furazidine turns urine dark yellow or brown.

To reduce side effects, it is recommended to take B vitamins, antihistamines and drink plenty of fluids. In case of severe side effects, the dose should be reduced or the drug should be stopped.

If, while taking the drug, adverse reactions occur that are not listed in the instructions for medical use, you must inform your doctor about this.

Furazidin tablets 50 mg No. 10x3

Name

Furazidin.

Release forms

Pills.

INN

Furazidin.

FTG

Antimicrobial agent; nitrofuran.

Basic physical and chemical properties

Tablets are round in shape, with a biconvex surface, from yellow to yellow with an orange tint, slightly uneven coloring of the surface, inclusions of a more intense color are allowed.

Compound

Active ingredient: 1 tablet contains furazidine - 50 mg; excipients: cellactose - 80 (a mixture of lactose monohydrate and microcrystalline cellulose in a ratio of 3:1), potato starch, magnesium stearate, polysorbate-80 (Tween-80).

Pharmacotherapeutic group

Antibacterial agents for systemic use. Nitrofuran derivatives. ATS code: J01XE03.

Pharmacological properties

Pharmacodynamics. Furazidin is a nitrofuran antibacterial agent with a bacteriostatic effect. Effective against gram-positive (Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus faecalis), gram-negative (Enterobacteriaceae, Klebsiella spp., Escherichia coli) bacteria. The high bacteriostatic activity of Furazidin is associated with the presence of an aromatic nitro group. Resistance to Furazidine develops slowly. Furazidin inhibits the enzyme systems of microorganisms, as well as other biochemical processes in the bacterial cell, which, in turn, causes disruption of the cytoplasmic membrane and cell wall of the bacterium. Pharmacokinetics Absorption. Furazidine is well absorbed from the digestive tract. Absorption of the drug mainly occurs from the distal part of the small intestine by passive diffusion (exceeds absorption from the proximal part several times). After a single dose of 200 mg, the maximum concentration of Furazidin is achieved in the blood plasma after 30 minutes, remains at this level for 1 hour, then slowly decreases. The bacteriostatic concentration of Furazidin in the blood plasma persists for 8-12 hours. Furazidin binds to blood plasma proteins. Metabolism/elimination. 10% of the dose taken is transformed in the liver and kidneys. If renal function is impaired, biotransformation of most of the applied dose occurs. The half-life of Furazidine is short (approximately 1 hour). Furazidine is excreted by the kidneys, mainly by tubular secretion (85%). 8-13% of Furazidin enters the urine unchanged, where its concentration on average is many times higher than the minimum concentration for most sensitive bacteria. The maximum concentration of Furazidin in urine is 5.7 mcg/ml. Furazidin penetrates well through the placental barrier.

Indications

Treatment of infectious and inflammatory diseases caused by microorganisms sensitive to furazidine in the urinary tract (cystitis, urethritis, pyelonephritis, prostatitis). Prevention of infectious complications after surgical interventions on the genitourinary system.

Contraindications

Hypersensitivity to furazidine, to other components of the drug, as well as to other drugs of the nitrofuran series; severe renal failure (creatinine clearance less than 30 ml/min); patients on hemodialysis or peritoneal dialysis; severe liver failure; deficiency of glucose-6-phosphate dehydrogenase. Polyneuropathy (including diabetic), porphyria, children under 18 years of age, pregnancy and lactation.

Directions for use and doses

For adults, Furazidin in a dose of 100-200 mg is prescribed orally 2-3 times a day, after meals, with plenty of water. The maximum daily dose is 600 mg. Depending on the form and severity of the disease, the course of treatment is 7-10 days. If necessary and there are no side effects, the course of treatment can be repeated 10-15 days after consultation with a doctor. If a dose is missed, the next dose should be taken as soon as the patient remembers. You should not take a double dose of the drug to replace a missed dose.

Adverse reactions

Criteria for the incidence of adverse reactions: very common (>10%), common (1-10%), uncommon (0.1-1%), rare (0.01-0.1%), very rare (

Overdose

Symptoms: acute toxic hepatitis, hemolytic or megaloblastic anemia, leukopenia, neurotoxicity (polyneuritis). Treatment: stop taking the drug, gastric lavage, prescribing antihistamines, calcium chloride, B vitamins; symptomatic therapy aimed at maintaining vital functions.

Use during pregnancy or breastfeeding

Use is contraindicated during pregnancy or breastfeeding.

Precautionary measures

The drug should be used with caution in the following cases: • renal dysfunction (use is contraindicated in severe renal failure); • anemia; • deficiency of B vitamins and folic acid; • lung diseases; • with long-term use of Furazidine, peripheral neuropathy (pain, loss of sensitivity in the area of the corresponding nerve) may develop; • in diabetes mellitus, the drug can cause polyneuropathy; • glucose/galactose malabsorption syndrome or lactase deficiency (excipients include cellactose-80). When using Furazidine, diarrhea may occur due to the drug's inhibition of the normal microflora of the large intestine. In case of long-term therapy, blood tests (white blood cell count), liver and kidney function tests, and pulmonary function should be monitored, especially in patients over 65 years of age. A pseudo-positive reaction to the presence of glucose in the urine is possible when using non-enzymatic methods. To prevent neuritis, it is advisable to simultaneously take antihistamines and B vitamins (nicotinamide, thiamine). During treatment, you should not drink alcohol, as it can increase the severity of side effects (increased heartbeat, pain in the heart, headache, nausea, vomiting, convulsions, decreased blood pressure, fever, anxiety). With long-term use of furazidine, the risk of developing drug-associated lung damage (toxic alveolitis, eosinophilic pneumonitis, pleural effusion) increases. Nitrofurans (including furazidine) may adversely affect testicular function, resulting in decreased sperm count, decreased motility, and abnormal changes in sperm morphology. With long-term use of furazidine, the natural synthesis of B vitamins and folic acid occurs.

Children

The drug is not used for children.

The ability to influence the reaction rate when driving a vehicle or working with other mechanisms

You should be careful when driving a vehicle or working with other mechanisms, and take into account the possibility of developing adverse reactions from the nervous system (dizziness, drowsiness).

Interaction with other drugs and other types of interactions

Agents that alkalinize urine reduce the therapeutic effect of Furazidin (accelerate the excretion of Furazidin in the urine). Agents that acidify urine (acids, including ascorbic acid, as well as calcium chloride) increase the concentration of Furazidin in the urine (its excretion in the urine slows down) and thus enhances the therapeutic effect of the drug, but at the same time the risk of increased toxicity increases. Use simultaneously with chloramphenicol, ristomycin and sulfonamides increases the inhibition of hematopoiesis. Due to the antagonism of the action of Furazidine with quinolones (nalidixic acid, oxolinic acid, norfloxacin), the simultaneous use of these drugs should be avoided. The use of probenecid and sulfinpyrazone reduces the excretion of Furazidine, which increases the risk of unwanted side effects and toxicity. The simultaneous use of Furazidin and antacids (which contain magnesium trisilicate) reduces the absorption of Furazidin. In case of renal failure, it is not recommended to use Furazidin simultaneously with aminoglycosides. The antibacterial effect of Furazidin is significantly enhanced when used simultaneously with antibiotics (penicillins and cephalosporins), and combines well with tetracycline and erythromycin. When used simultaneously with MAO inhibitors and foods containing tyramine (beer, wine, cheese, beans, smoked meats), there is a risk of developing a hypertensive crisis.

Best before date

2 years.

Storage conditions

In original packaging, at a temperature not exceeding 25°C. Keep out of the reach of children.

Package

Tablets No. 10 in a blister, 3 blisters in a pack.

Vacation conditions

On prescription.

Buy Furazidin tablets 50 mg No. 10x3 in the pharmacy

Price for Furazidin tablets 50 mg No. 10x3

Instructions for use for Furazidin tablets 50 mg No. 10x3

FURAMAG

Pharmacokinetics

Absorption occurs in the small intestine by passive diffusion.
The absorption of nitrofurans from the distal segment of the small intestine exceeds the absorption from the proximal and middle segments by 2 and 4 times, respectively (should be taken into account during the simultaneous treatment of urogenital infections and diseases of the gastrointestinal tract, including chronic enteritis). Nitrofurans are poorly absorbed in the colon. Furamag, being a mixture of furazidine potassium and magnesium hydroxycarbonate in a 1:1 ratio, when administered orally, has a higher bioavailability than simple furazidine (after taking the Furamag® capsule in the acidic environment of the stomach, the conversion of potassium furazidine into poorly soluble furazidine does not occur).

Furazidin is distributed evenly in the body. The high content of the active substance in the lymph is clinically important (it delays the spread of infection along the lymphatic tract). In bile its concentration is several times higher than in blood serum, and in cerebrospinal fluid it is several times lower than in serum. The content of furazidin in saliva is 30% of its concentration in blood serum. The concentration of furazidin in the blood and tissues is relatively small, which is associated with its rapid release, while the concentration in the urine is much higher than in the blood. The maximum concentration in the blood lasts from 3 to 7 or 8 hours; furazidin is detected in the urine 3-4 hours after application.

Unlike nitrofurantoin (furadonin), the urine pH does not change after taking Furamag®. 4 hours after taking the drug Furamag®, the concentration of furazidine in the urine significantly exceeds the concentration that is formed after taking the same dose of the drug Furagin. Excretion through the kidneys occurs by glomerular filtration and tubular secretion (85%), partially undergoing reverse reabsorption in the tubules. At low concentrations of furazidin in the urine, the process of filtration and secretion predominates; at high concentrations, secretion decreases and reabsorption increases. Furazidine, being a weak acid, does not dissociate in acidic urine and undergoes intense reabsorption, which can enhance the development of systemic side effects. When the urine becomes alkaline, the excretion of furazidine increases. Furazidine is slightly biotransformed (less than 10% of the administered dose); with a decrease in renal excretory function, the metabolic rate increases.